Cellectis is a clinical-stage biopharmaceutical company based in Paris, France. It works on gene editing and cell therapy, developing engineered immune cells for treating cancers and other serious diseases. Its science uses molecular tools that target specific DNA sequences, and its programmes include off-the-shelf CAR T-cell candidates for patients with blood cancers. The company also licenses its gene-editing technology to partners in medicine and agriculture, and it carries out research and manufacturing work at sites in France and the United States.
The shares are listed on the London Exchange in UK under the code 0WA2, and the price on this page is in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Market X-Ray · price-based
Weak price profile
Ranks #3769 of 3787 on the London Exchange · confidence High
What this score is, and is not
It describes how this stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is. That fundamental X-Ray needs financial statements, which we do not have for UK yet.
TrendWeak
2/100
Below its long-term averages and far from its highs.
See the numbers →
Above 200-day average-65.9%
From 52-week high-79.7%
MomentumWeak
2/100
Lagging most stocks on this exchange.
See the numbers →
3-month return-62.4%
6-month return-72.2%
12-month, skipping last month-57.6%
Stability (higher is calmer)Weak
6/100
Volatile, with deep drawdowns.
See the numbers →
Volatility, 1 year (lower is calmer)90.6%
Worst drawdown, 1 year (smaller is calmer)-79.9%
LiquidityWeak
8/100
Thinly traded: prices can jump and exits can be hard.
See the numbers →
Avg daily value traded0.00M EUR
Zero-volume days16.7%
IncomeNone
–/100
Pays no dividend.
See the numbers →
Years with dividends0
Price-based X-Ray. The fundamental X-Ray (financial health, valuation, growth, fair value) is available for US stocks today. It will follow for UK when fundamentals data for this market is added. All UK stocks.
52-wk range 0.927 – 4.745Daily closes, split-adjusted
Signals
50-day average1.845
200-day average2.748
Golden/death cross (60d)None
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)0.739
Technical summary
Daily
Strongly bearish
3 bullish · 0 neutral · 13 bearish
Weekly
Strongly bearish
1 bullish · 0 neutral · 11 bearish
Monthly
Strongly bearish
0 bullish · 1 neutral · 7 bearish
Moving averages (daily)
SMA 10
1.01
Bearish
EMA 10
1.02
Bearish
SMA 20
1.12
Bearish
EMA 20
1.16
Bearish
SMA 50
1.84
Bearish
EMA 50
1.62
Bearish
SMA 100
2.21
Bearish
EMA 100
2.07
Bearish
SMA 200
2.75
Bearish
EMA 200
2.44
Bearish
Oscillators (daily)
RSI (14)
27.18
Bullish
MACD (12, 26)
-0.22
Bearish
Momentum (12)
-23.47
Bearish
Stochastic %K (14)
0.49
Bullish
Williams %R (14)
-99.51
Bullish
CCI (20)
102.9
Bearish
Pivot points (classic, last session)
S3
-1.61
S2
-0.34
S1
0.30
Pivot
1.57
R1
2.21
R2
3.48
R3
4.12
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Prices are end-of-day closes in EUR. Educational only, not financial advice.
